AstraZeneca Delivers Strong Growth and Scientific Momentum in Q3 2025 Results
AstraZeneca has reported a strong set of results for the first nine months and third quarter of 2025, highlighting double-digit revenue growth, rising earnings, and record progress in its late-stage pipeline.




















